Prostate Cancer

• Androgen Receptor Axis Dependence: The prostate is an androgen-dependent organ where testosterone (converted to dihydrotestosterone by 5-α reductase) binds the androgen receptor, driving epithelial proliferation and survival. Dysregulation of AR signaling is central to prostate cancer pathogenesis. In early disease, malignant cells remain dependent on androgens for survival, which forms the rationale for androgen deprivation therapy (ADT). Ligand-independent AR activation can occur through gene amplification, mutations causing constitutive activation, or cross-talk with growth factor pathways (MAPK, PI3K), allowing progression to castration-resistant prostate cancer (CRPC) despite low testosterone levels.

• Genetic Alterations: Early carcinogenic events include inactivation of the PTEN tumor suppressor gene (loss in ~40% of prostate cancers), which normally inhibits PI3K/AKT signaling; mutations in TP53 (loss-of-function) leading to genomic instability; and BRCA2 germline mutations (associated with earlier onset, more aggressive disease). Recurrent gene fusions, particularly TMPRSS2-ERG fusion (occurring in ~50% of localized cancers), result from chromosomal rearrangements placing the oncogenic transcription factor ERG under control of the prostate-specific promoter TMPRSS2, driving aberrant gene expression. These fusions are more common in higher-grade tumors and may predict response to therapy.

• Progressive Clonal Evolution and Metastatic Cascade: Localized prostate tumors progress through intermediate and high-grade lesions before acquiring ability to invade through the prostatic capsule, intravasate into vasculature, and establish distant metastases. Epithelial-to-mesenchymal transition (EMT) promotes invasion and survival in circulation. Metastatic competence requires resistance to anoikis (death from loss of cell-matrix contact) and ability to establish micrometastases in bone (the primary site of prostate cancer metastasis due to preferential homing mechanisms), liver, and lungs. Bone tropism is mediated by chemokine signaling, particularly CXCL12/CXCR4 axis, explaining why prostate cancer frequently causes osteoblastic (sclerotic) bone metastases rather than osteolytic lesions. Within bone microenvironment, tumor cells interact with osteoblasts, osteoclasts, and immune cells, which provide growth signals and promote treatment resistance.

• Hallmarks-of-Cancer Perspective: Prostate cancers develop through sequential acquisition of hallmark capabilities: sustained proliferative signaling (AR pathway), evasion of growth suppressors (PTEN/TP53 loss), resistance to cell death (AR-driven survival signals), replicative immortality (telomerase reactivation in advanced disease), induced angiogenesis (VEGF signaling), and tissue invasion/metastasis (EMT program). The tumor microenvironment—including cancer-associated fibroblasts, immune infiltrates, and angiogenic factors—plays crucial roles in progression and therapeutic resistance.

• Age: The most powerful risk factor; incidence increases exponentially after age 50, with median age at diagnosis of 66 years. This reflects the multi-hit carcinogenesis model requiring accumulation of multiple molecular alterations over decades.

• African American Ethnicity: African American men have 1.6-2.0 fold higher incidence and significantly higher mortality compared to Caucasian men, with earlier age at onset and more aggressive disease phenotypes. Contributors include possible genetic susceptibility (polymorphisms in genes like RNASEL, ELAC2), higher prevalence of risk alleles, socioeconomic factors limiting healthcare access, and potential environmental exposures. This disparity necessitates culturally tailored screening and treatment discussions.

• Family History and Hereditary Syndromes: Men with first-degree relatives (father, brother, son) with prostate cancer have 2-3 fold increased risk; risk increases further with multiple affected relatives or early-age diagnosis (before 65 years). BRCA2 germline mutations confer highest hereditary risk (lifetime prostate cancer risk ~60%) with notably aggressive disease; BRCA1 mutations also increase risk. Lynch syndrome (mismatch repair gene defects: MLH1, MSH2, MSH6, PMS2) increases prostate cancer risk 2-3 fold. Other high-risk genes identified through genome-wide association studies (GWAS) include HOXB13, PALB2, and CHEK2. Men with hereditary cancer syndromes warrant earlier screening discussions and more intensive monitoring.

• Prior History of Prostate Cancer: Men with prior diagnosis have risk of recurrence or second primary tumors, requiring continued surveillance.

• Obesity and Metabolic Factors: Increased BMI, particularly in the context of metabolic syndrome, associates with higher risk of advanced and more aggressive prostate cancer, possibly through insulin-like growth factor signaling and chronic inflammation.

• Hormonal Factors: Elevated testosterone and androgen sensitivity theoretically increase risk (evidenced by rarity in hypogonadal men), though clinical application of hormone measurement for risk stratification is limited.

• Dietary Factors: High-fat diet, particularly saturated fat intake, may increase risk; conversely, diets rich in lycopene (tomato products), soy, cruciferous vegetables, and omega-3 fatty acids may offer modest protective effects. Evidence remains inconclusive for clinical decision-making.

• Inflammation and Infection: Chronic prostatitis and sexually transmitted infections (chlamydia) have been epidemiologically associated with increased prostate cancer risk, possibly through chronic inflammatory signaling.

• Prior Radiation: Men with prior pelvic radiation for other malignancies have increased prostate cancer risk.

• Lower Urinary Tract Symptoms (LUTS): Dysuria, urinary frequency, nocturia, weak urinary stream, hesitancy, and incomplete emptying occur when tumor growth obstructs urethral or bladder outlet flow. These symptoms are often indistinguishable from benign prostatic hyperplasia (BPH) and may be subtle in early disease. Acute urinary retention can occur with rapid tumor growth or in setting of spinal metastases compressing cauda equina.

• Hematuria and Hemospermia: Gross or microscopic hematuria results from tumor invasion eroding into urethra or bladder; hemospermia (blood in semen) suggests direct involvement of seminal vesicles or ejaculatory ducts.

• Bone Pain and Skeletal Symptoms: Metastatic prostate cancer has strong predilection for osteoblastic bone metastases (predominantly in lumbar spine, pelvis, ribs, femur). Patients present with bone pain, typically described as dull, aching, and worsening at night. Lytic bone lesions can cause pathologic fractures. Spinal metastases risk spinal cord compression presenting with lower extremity weakness, sensory loss, or bowel/bladder dysfunction—a urologic emergency.

• Constitutional Symptoms: Weight loss, fatigue, night sweats indicate advanced disease burden. Anemia may cause dyspnea and fatigue.

• Lymphedema of Lower Extremities: Results from involvement of pelvic and inguinal lymph nodes obstructing lymphatic drainage; indicates regional nodal involvement.

• Physical Exam Findings: On digital rectal examination (DRE), prostate cancer may present as a hard, irregular nodule with loss of normal mobility and induration that may extend beyond prostatic boundaries suggesting extraprostatic extension. However, most early-stage cancers detected by PSA have normal DRE. In advanced disease, palpable supraclavicular or inguinal lymphadenopathy suggests metastatic involvement.

• Important Clinical Variants: Some presentations reflect disease aggressiveness: rapidly progressive disease with short symptom duration suggests high-grade/aggressive histology; in contrast, asymptomatic PSA elevation discovered on screening may represent indolent disease. Neuroendocrine prostate cancer is a rare, highly aggressive histologic variant presenting with rapid progression, high PSA, and propensity for visceral metastases; often emerges after ADT resistance.

• Prostate-Specific Antigen (PSA) Testing and Interpretation: PSA is a serine protease produced by prostate epithelium (both benign and malignant); it is organ-specific but not cancer-specific. PSA screening remains controversial. Current guidelines recommend shared decision-making for men aged 50-69 (or 40-45 for those with family history, African Americans, or high-risk genotypes). Absolute PSA value interpreted in context: PSA <4 ng/mL traditionally considered "normal" but cancer can occur below this threshold; PSA 4-10 ng/mL requires further evaluation; PSA >10 ng/mL strongly suggests need for biopsy. PSA velocity (change over time; >0.75 ng/mL/year suggests higher risk) and PSA density (PSA divided by prostate volume on ultrasound; >0.15 ng/mL/cm³ more concerning) refine interpretation. Free PSA percentage (free PSA divided by total PSA): lower free PSA percentage (<25%) increases cancer likelihood. For men on 5-α reductase inhibitors (finasteride, dutasteride), PSA should be multiplied by 1.5 to correct for drug-related reduction.

• Risk Calculators and Biomarkers: PCPT (Prostate Cancer Prevention Trial) risk calculator and ERSPC (European Randomized Study of Screening for Prostate Cancer) risk calculator predict probability of prostate cancer detection on biopsy. Newer biomarkers (PSA4Kscore, PHI, 4Kscore, SelectMDx) combine PSA with additional serum or urine markers to improve specificity for high-grade cancer, reducing unnecessary biopsies. Prostate Health Index (PHI) and 4Kscore have moderate evidence supporting use to reduce biopsy rate while maintaining sensitivity for clinically significant cancer.

• Digital Rectal Examination (DRE): Though declining in routine screening, an abnormal DRE (hard, irregular nodule; loss of normal contours; asymmetry; induration) warrants biopsy even with PSA <4 ng/mL. Sensitivity ~70% but specificity only ~50-60% for cancer.

• Transrectal Ultrasound (TRUS)-Guided Prostate Biopsy: Gold standard for tissue diagnosis; indicated for men with elevated PSA, abnormal DRE, or concerning biomarkers. Systematic biopsy with 10-12 cores obtained; contemporary practice increasingly uses MRI-targeted biopsy (mpMRI followed by fusion biopsy or in-bore biopsy) showing improved detection of clinically significant cancers and reduction of low-grade/indolent cancer detection. Biopsy complications include hematuria (~30%), hematochezia (~20%), hematospermia (~35%), infection/sepsis (1-3%), and retention (1-2%).

• Prostate MRI (mpMRI): Multiparametric MRI (T2-weighted imaging, diffusion-weighted imaging [DWI], perfusion imaging, MR spectroscopy) provides superior soft tissue characterization, superior detection of clinically significant cancer, and better assessment of extraprostatic extension compared to ultrasound. PI-RADS scoring (1-5 scale) standardizes interpretation; PI-RADS ≥3 considered significant and warrants biopsy. MRI provides superior imaging for local staging.

• Gleason Score and Grade Groups: Histologic grading is most powerful prognostic factor for localized disease. Gleason scoring assigns scores 1-5 to primary and secondary tumor patterns (sum ranges 2-10); Gleason 6 represents low-grade, 7 intermediate, 8-10 high-grade disease. In 2016, Gleason Grade Group (GGG) system simplified interpretation: GGG 1 (Gleason ≤6), GGG 2 (Gleason 3+4=7), GGG 3 (Gleason 4+3=7), GGG 4 (Gleason 8), GGG 5 (Gleason 9-10). Grade groups correlate with risk of biochemical recurrence, metastasis, and prostate cancer mortality. Higher grade groups guide intensity of treatment.

• TNM Staging and Risk Stratification: Clinical stage determined by DRE and imaging; pathologic stage from surgical specimens. T-stage: T1 (impalpable, PSA-detected); T2 (palpable, confined to prostate); T3 (extraprostatic extension); T4 (fixed, invading rectum/bladder). N-stage: N0 (no regional nodes); N1 (regional nodal metastases). M-stage: M0 (no distant mets); M1a (non-regional nodes); M1b (bones); M1c (other visceral mets). D'Amico risk stratification widely used: low-risk (PSA <10, Gleason ≤6, T1-2a), intermediate-risk (PSA 10-20 OR Gleason 7 OR T2b-2c), high-risk (PSA >20 OR Gleason 8-10 OR T3-4). NCCN risk groups provide more granular stratification. Risk stratification drives treatment decisions.

• Staging Imaging: For localized low-risk disease, routine staging imaging not recommended (low yield of metastases). For intermediate/high-risk disease, consider bone scan or NaF-PET/CT and pelvic CT/MRI for nodal assessment. For metastatic disease, whole-body bone scan, CT chest/abdomen/pelvis, and PET/CT (prostate cancer-specific tracers like 68Ga-PSMA-11 with superior sensitivity/specificity compared to conventional imaging) provide more accurate staging.

• Differential Diagnosis Considerations: Elevated PSA and DRE abnormality may reflect benign prostatic hyperplasia, prostatitis, or urinary tract infection rather than cancer; timing PSA measurement >4 weeks after LUTS, instrumentation, or ejaculation minimizes false elevation. Bone pain in older men may be due to osteoarthritis, metastatic disease from other malignancies, or osteomyelitis rather than prostate cancer metastases.

• Active Surveillance (AS): Appropriate for men with low-risk or favorable intermediate-risk localized prostate cancer (PSA <10, Gleason ≤6/GGG 1, T1-2a, life expectancy >10-15 years), capturing ~20-30% of newly diagnosed men. Rationale: most low-grade, localized cancers progress very slowly or not at all during patient lifetime; avoiding/delaying radical treatment reduces morbidity. Protocol involves regular PSA testing (every 3-6 months initially, then annually), DRE, and repeat biopsy at 1-2 years and periodically thereafter to confirm absence of grade progression or new high-risk findings. Triggers for intervention include

Disease-related — emergencies first

• Metastatic epidural spinal cord compression (emergency): vertebral body metastases (spread favored by the valveless Batson venous plexus) expand posteriorly into the epidural space. Signaled by new or escalating back pain worse when supine, then leg weakness, a sensory level, and late bowel/bladder dysfunction. NCCN guidance is immediate corticosteroids (dexamethasone) plus urgent MRI of the entire spine, followed by radiation or decompressive surgery — do not wait for the neuro deficit to declare itself.
• Obstructive uropathy (emergency if bilateral): tumor at the bladder base or bulky pelvic nodes obstruct the ureters or bladder outlet, producing hydronephrosis, post-renal AKI, and hyperkalemia. Signaled by rising creatinine with a distended bladder or bilateral hydronephrosis; treat with drainage (catheter, nephrostomy, or stents).
• Pathologic fracture and bone pain: metastases are osteoblastic/sclerotic, so bone is dense but structurally disorganized. Alkaline phosphatase is markedly elevated; serum calcium is typically normal or low (calcium is consumed by blastic bone), unlike the hypercalcemia of lytic myeloma or breast cancer.
• Chronic DIC: tumor tissue factor and urokinase-type plasminogen activator drive consumptive coagulopathy — oozing, low platelets, low fibrinogen, elevated D-dimer.
• Marrow replacement: anemia with a leukoerythroblastic smear (nucleated RBCs, teardrop cells).
• Neuroendocrine/small-cell transformation: rapid visceral progression with a disproportionately low PSA after prolonged AR-targeted therapy.

Treatment-related

• Radical prostatectomy: erectile dysfunction (cavernous nerve injury) and stress incontinence (external sphincter injury); PSA should become undetectable — any detectable value signals recurrence.
• Radiation: radiation proctitis (rectal bleeding, urgency), hemorrhagic cystitis, urethral stricture, and late second malignancies of bladder/rectum.
• GnRH agonist (leuprolide) flare: initial LH surge raises testosterone and can precipitate cord compression or retention; blocked by a first-generation antiandrogen (bicalutamide) or avoided with a GnRH antagonist (degarelix, relugolix).
• ADT long-term: hot flashes, sarcopenia, gynecomastia, insulin resistance, and accelerated bone loss — NCCN and ASCO advise baseline DEXA, calcium/vitamin D, and a bone-modifying agent (denosumab or zoledronic acid) for high fracture risk.
• Abiraterone: CYP17 blockade causes mineralocorticoid excess (hypertension, hypokalemia, edema) — hence co-administered prednisone; monitor LFTs. Enzalutamide: fatigue, falls, seizure risk. Docetaxel: febrile neutropenia (emergency) and neuropathy. Radium-223: myelosuppression.

• Zonal anatomy is the classic distractor: prostate cancer arises in the peripheral zone (posterior, hence palpable on DRE); BPH arises in the transition zone (periurethral, hence obstructive symptoms). A stem describing a hard posterior nodule is cancer; one describing a smooth, symmetrically enlarged gland with nocturia is BPH.
• Osteoblastic metastases with a high alkaline phosphatase and normal-to-low calcium are the signature. If the stem gives hypercalcemia with lytic lesions, reconsider myeloma, breast cancer, or squamous cell lung cancer.
• Back pain in a man with known prostate cancer is cord compression until proven otherwise. Single best next step: corticosteroids plus emergent whole-spine MRI — not plain films, not a bone scan, and not "start opioids and follow up."
• PSA is organ-specific, not cancer-specific. Prostatitis, BPH, recent ejaculation, catheterization, and biopsy all raise it. Tissue diagnosis requires biopsy, so "start ADT based on PSA alone" is always wrong.
• 5-α reductase inhibitors halve PSA — multiply the measured value by 2 (roughly, after ~6-12 months of therapy) before interpreting it in a man on finasteride or dutasteride.
• The flare phenomenon is the single most tested pharmacology point: leuprolide (GnRH agonist) transiently surges testosterone before downregulating GnRH receptors. Pretreat with an antiandrogen (bicalutamide) or choose a GnRH antagonist (degarelix, relugolix), which produces no flare — especially in a patient with vertebral metastases.
• Screening framing: the USPSTF gives PSA screening a C recommendation (individualized shared decision-making) for men 55-69 and a D recommendation (do not screen) for men 70 and older. Reflexively ordering PSA in an 80-year-old with limited life expectancy is the trap.
• Gleason 3+4 (Grade Group 2) is not the same as 4+3 (Grade Group 3) — the primary pattern dominates prognosis. Grade Group 1 disease in a man with long life expectancy belongs on active surveillance, not on immediate prostatectomy.
• BRCA2 is the association examiners test: earliest onset, most aggressive course, and the reason germline testing and PARP inhibitor eligibility appear in metastatic stems.